Upload
vodat
View
217
Download
2
Embed Size (px)
Citation preview
Pathophysiology of Tuberculosis
PHCL 415Hadeel Alkofide
May 2010
1
Learning Objectives
• Understand the pathophysiology of tuberculosis (TB)
• Understand clinical manifestations of TB
• Understand why certain patients develop TB
• Discuss Signs & symptoms of TB
• Learn the basic concept in diagnosing TB
• Compare the risk for active TB disease among patients
2
Outline
• Introduction
• Epidemiology
• Risk Factors
• Etiology
• Transmission
• Pathophysiology
• Clinical Presentation
• Diagnosis
3
Introduction
4
Introduction
• Tuberculosis TB is caused by Mycobacterium tuberculosis, an aerobic, non spore forming bacillus that resists decolorizationby acid alcohol after staining
• Referred to as an acid fast bacillus (AFB)
• Replicate slowly
• M. tuberculosis thrives in environments where the oxygen tension is relatively high
5
Epidemiology
6
Epidemiology
• 2 billion people are infected by M. tuberculosis
• 2 to 3 million people die from active TB each year despite the fact that it is curable
• In the United States, about 13 million people are latently infected with M. tuberculosis, meaning that they are not currently sick but that they could fall ill with TB at any time
7
Epidemiology
• In Saudi Arabia, what do you think?
8
Risk Factors
9
Risk Factors for infection
• Location & place of birth
• Ethnicity, age & gender
• Coinfection with Human Immunodeficiency Virus (HIV)
10
Risk Factors for Disease
• Once infected with M. tuberculosis, a person's lifetime risk of active TB is approximately 10%
• The greatest risk for active disease occurs during the first 2 years after infection
• Children younger than 2 years of age and adults older than 65 years of age have two to five times greater risk for active disease compared with other age groups
• Patients with underlying immune suppression (e.g., renal failure, cancer, and immunosuppressive drug treatment) have 4 to 16 times greater risk than other patients
11
Risk Factors for Disease
• HIV-infected patients with M. tuberculosis infection are 100 times more likely to develop active TB than normal hosts
• HIV-infected patients have an annual risk of active TB of approximately 10%, rather than a lifetime risk at that rate
• Therefore, all patients with HIV infection should be screened for tuberculous infection, and those known to be infected with M. tuberculosis should be tested for HIV infection
12
Etiology
13
Etiology
• M. tuberculosis is a bacillus with a waxy outer layer
• It is 1 to 4 microns in length, & under the microscope, it is either straight or slightly curved in shape
• It does not stain well with Gram stain, so the Ziehl-Neelsenstain or the fluorochrome stain must be used instead
• After Ziehl-Neelsen staining with carbol-fuchsin, mycobacteriaretain the red color despite acid–alcohol washes
• Hence they are called acid-fast bacilli
14
Tuberculosis bacilli
TB Culture
Transmission
16
Transmission
• Tubercle bacilli are transmitted through air by aerosolized droplet nuclei that are produced when a person with laryngeal TB:
Cough
Sneezes
Speaks
Pathophysiology
18
Pathogenesis
Latent TB
• Not infectious and cannot transmit the organism
Active TB
• Infective
Immune Response
• Good T-lymphocyte responses are essential to controlling M. tuberculosis infections
• T-lymphocytes activate macrophages that, in turn, engulf & kill mycobacteria
• CD4+ cells are the primary T cells involved
• CD4+ T cells produce interferon (INF-) & other cytokines, that coordinate the immune response to TB
• Because CD4+ cells are depleted in HIV patients, these patients are unable to have an adequate defense to TB
20
Immune Response
• M. tuberculosis has several ways of evading or resisting the host immune response
• In particular, M. tuberculosis can inhibit the fusion of lysosomes to phagosomes inside macrophages
• This prevents the destructive enzymes found in the lysosomesfrom getting to the bacilli captured in the phagosomes
• This allows time for M. tuberculosis to escape into the cytoplasm
21
Immune Response
• Lipoarabinomannan, the principal structural polysaccharide of the mycobacterial cell wall, inhibits the host immune response
• Lipoarabinomannan induces immunosuppressive cytokines, thus blocking macrophage activation
22
Immune Response
• These survival mechanisms make M. tuberculosis a particularly difficult organism to control
• Any defects in the host immune system make it likely that M. tuberculosis will not be controlled & that active disease will ensue
23
Immune ResponseInhalation the droplet nuclei containing M.tuberculosis organisms
Settle into the bronchioles and alveoli of the lung
Taken into alveolar macrophages & remain viable multiplying within the cells
Tubercle bacilli spread via lymphatic system to the lymph nodes
T lymphocyte mediated immune response developed, limit multiplication & spread of bacilli
After 14 to 21
days of replication
Primary Infection
• Primary infection usually results from inhaling airborne particles that contain M. tuberculosis
• These particles, called droplet nuclei, contain one to three bacilli & are small enough (1 to 5 mm) to reach the alveolar surface
• Ingestion (swallowing) & inoculation (puncture wound) are other rare pathways to acquire M. tuberculosis infection
25
Primary Infection
• The progression to clinical disease depends on 3 factors
1. The number of M. tuberculosis organisms inhaled (infecting dose)
2. The virulence of these organisms
3. The host's cell-mediated immune response
26
Primary Infection
• At the alveolar surface, the bacilli that were delivered by the droplet nuclei are ingested by pulmonary macrophages
• If these macrophages inhibit or kill the bacilli, infection is aborted
• If the macrophages cannot do this, the organisms continue to multiply
27
Primary Infection
• The macrophages eventually rupture, releasing many bacilli, & these mycobacteria are then phagocytized by other macrophages
• This cycle continues over several weeks until the host is able to mount a more coordinated response
28
Primary Infection
• Some of the intracellular organisms are transported by the macrophages to regional lymph nodes
• The cycle of phagocytosis & cell rupture continues
• During lymph node involvement, M. tuberculosis may spreads throughout the body through the bloodstream
• When this intravascular dissemination occurs, M. tuberculosis can infect any tissue or organ in the body
29
Primary Infection
• After about 3 weeks of infection, T lymphocytes are presented with M. tuberculosis antigens
• These T cells become activated & begin to secrete INF- & the other cytokines
• First, T-lymphocytes stimulate macrophages to become bactericidal
• This process of creating activated microbicidal macrophages is known as cell-mediated immunity
30
Primary Infection
• At the same time that cell-mediated immunity occurs, delayed-type hypersensitivity also develops through the activation & multiplication of T lymphocytes
• Delayed-type hypersensitivity refers to the cytotoxic immune process that kills nonactivated immature macrophages that are permitting intracellular bacillary replication
• The bacilli released from the immature macrophages then are killed by the activated macrophages
31
Primary Infection
• Over 1 to 3 months, activated lymphocytes reach an adequate number, & tissue hypersensitivity results
• This is shown by a positive tuberculin skin test
• Any remaining mycobacteria are believed to reside primarily within granulomas or within macrophages
32
Primary Infection
• At this point, the infection is largely under control, & bacillary replication falls off dramatically
33
Primary Infection
• 90% of infected patients have no further clinical manifestations
• Most patients only show a + skin test (70%), whereas some also have radiographic evidence of stable granulomas (20%)
• 5% of patients (usually children, elderly, & immunocompromised) experience "progressive primary" disease
• Because of this risk of severe disease, very young, elderly, & immunocompromised patients, including those with HIV, should be evaluated and treated for latent or active TB
34
Reactivation of Disease
• 10% of infected patients develop reactivation disease at some point in their lives
• Nearly half of these cases occur within 2 years of infection
• The lungs is the most common sites for reactivation (85% of cases)
35
Extrapulmonary & Miliary TB
• Caseating granulomas at extrapulmonary sites can undergo liquefaction, releasing tubercle bacilli & causing symptomatic disease
• Extrapulmonary TB without concurrent pulmonary disease is uncommon in normal hosts but more common in HIV-infected patients
• Because of these unusual presentations, the diagnosis of TB is difficult & often delayed in immunocompromised hosts
36
Extrapulmonary & Miliary TB
• Lymphatic & pleural diseases are the most common forms of extrapulmonary TB, followed by bone, joint, genitourinary, & meningeal TB
• Left untreated, these forms will spread to other organs and may result in death
37
Extrapulmonary & Miliary TB
• Occasionally, a massive inoculum of organisms enters the bloodstream, causing a widely disseminated form of the disease known as miliary TB
• It can be rapidly fatal
• Miliary TB is a medical emergency requiring immediate treatment.
38
Pathogenesis of TB
Influence of HIV on Pathogenesis
• HIV infection is the largest risk factor for active TB
• As CD4+ lymphocytes multiply in response to the mycobacterial infection, HIV multiplies within these cells & selectively destroys them
• In turn, the TB-fighting lymphocytes are depleted
• This vicious cycle puts HIV-infected patients at 100 times the risk of active TB compared with HIV-negative people
40
Influence of HIV on Pathogenesis
• HIV-infected patients who are infected with TB deteriorate more rapidly unless they receive antimycobacterialchemotherapy
• Because TB can be very dangerous in HIV-positive patients, they should be screened for tuberculous infection or disease soon after they are shown to be HIV-positive
41
Clinical presentation
42
Clinical Presentation
• The onset of TB is gradual
• Many patients do not seek medical attention until more dramatic symptoms, such as frank hemoptysis, occur
• At this point, patients typically have large cavitary lesions in the lungs. These cavities are loaded with M. tuberculosis
• Expectoration or swallowing of infected sputum may spread the disease to other areas of the body
43
Clinical Presentation
Symptoms
• Weight loss
• Fatigue
• Productive cough
• Fever
• Night sweats
• Frank hemoptysis
44
Clinical Presentation
Physical Examination
• Dullness to chest percussion
• Rales observed frequently on auscultation
45
Clinical Presentation
Laboratory Tests
• Moderate elevations in the white blood cell (WBC) count with a lymphocyte predominance
46
Clinical Presentation
Chest Radiography
• Patchy or nodular infiltrates in the apical areas of the upper lobes or the superior segment of the lower lobes
• Cavitation that may show air-fluid levels as the infection progresses
47
Clinical Presentation
TB in HIV-infected patients
• Patients with HIV & TB have atypical presentations
• As their CD4+ counts decline, they are less likely to have positive skin tests or fever
• Pulmonary radiographic findings may be minimal or absent
• HIV-positive patients have a higher incidence of extrapulmonary TB & are more likely to present with progressive disease
48
Clinical Presentation
Extrapulmonary TB
• Extrapulmonary TB presents as a slowly progressive decline in organ function
• Patients may have low-grade fever
• Patients with genitourinary TB may present with hematuria
• Tuberculous arthritis occur most commonly in the elderly & usually affect the lower spine & weight-bearing joints
• Abnormal behavior, headaches, or convulsions suggest tuberculousmeningitis
49
Clinical Presentation
The Elderly
• TB in the elderly is easily confused with other respiratory diseases
• Many clinical findings are muted or absent altogether
• Compared with younger patients, TB in the elderly is far less likely to present with + skin tests, fevers, night sweats, sputum production, or hemoptysis
• Mental status changes are twice as common in the elderly, & mortality is six times higher
50
Clinical Presentation
The Children
• TB in children, especially those younger than 12 years of age, may present as a typical bacterial pneumonia
• Clinical disease often begins 1 to 2 months after exposure & precedes skin-test positivity
• Unlike adults, pulmonary TB in children often involves the lower and middle lobes
• TB can be rapidly fatal in a child, & it requires prompt chemotherapy
51
Diagnosis
52
Clinical Presentation
Skin Test
• Mantoux test. It uses tuberculin purified protein derivative (PPD)
• PPD is placed intracutaneously on the forearm
• This injection should produce a small, raised wheal
• Read the test in 48 to 72 hours
• The area of induration (the "bump") is the important end point, not the area of redness
53
Clinical Presentation
54
Criteria for Tuberculin Positivity by Risk Group
Reaction 5 mm of Induration Reaction 10 mm of IndurationReaction 15 mm of
Induration
HIV-positive personsRecent immigrants (in the last 5 y) from high-
prevalence countriesPersons with no risk
factors
Recent contacts of TB case patients
Injection-drug users
Fibrotic changes on chest radiograph consistent with
prior TB
Residents & employees of the following high-risksettings: prisons; nursing homes & other long-term care facilities for the elderly; hospitals &
homeless shelters
Patients with organ transplants & other immunosuppressed
patients (receiving the equivalent of 15 mg/day of
prednisone for 1 mo or more)
Mycobacteriology laboratory personnel
Persons at high risk: DM; chronic renal failure; some hematologic disorders (e.g., leukemias & lymphomas); malignancies (e.g., carcinoma of
the head or neck & lung); weight loss of 10% of IBW; gastrectomy
Children < 4 y of age or infants, children, & adolescents exposed to adults at high risk
Clinical Presentation
Skin Test
• The PPD skin test is an imperfect diagnostic tool
• Up to 20% of patients with active TB are falsely skin-test–negative, presumably because their immune systems are overwhelmed
• False-positive results are more common in low-risk patients & those recently vaccinated with BCG
• Despite BCG vaccination, one should not ignore a positive PPD result
55
Clinical Presentation
Other Tests
• Positive sputum smear for AFB
• Isolation of organism (TB culture)
• By using sputum sample in pulmonary TB
• Sputum collected in the morning usually has the highest yield
• Daily sputum collection over 3 consecutive days is recommended
56
References
• Pharmacotherapy: A PathophysiologicApproach, 7e
• Pathophysiology of Disease: An Introduction to Clinical Medicine, 6e
• Applied Therapeutics: The Clinical Use of Drugs, 9e
57
Learning Objectives
• Understand the pathophysiology of tuberculosis (TB)
• Understand clinical manifestations of TB
• Understand why certain patients develop TB
• Discuss Signs & symptoms of TB
• Learn the basic concept in diagnosing TB
• Compare the risk for active TB disease among patients
58
Thank You
59